Liquidia Corporation (LQDA) AI Stock Analysis

Liquidia Corporation is a Morrisville, North Carolina-based biopharmaceutical company founded in 2004 that employs 216 people. The firm focuses on development, manufacturing, and commercialization of therapeutic solutions to address unmet medical needs. Its flagship product candidate is YUTREPIA, an inhaled dry powder formulation of treprostinil created for the treatment of pulmonary arterial hypertension. In addition to advancing pulmonary therapies, Liquidia distributes generic treprostinil injection across the United States to improve treatment accessibility. The company also pursues strategic collaborations and partnerships to broaden its reach in the biopharmaceutical sector.

Liquidia's annual revenue rose from $12.9M in FY2021 to $15.9M in FY2022 and $17.5M in FY2023, before declining 20.0% to $14.0M in FY2024. In FY2025, revenue surged 1031.2% to $158.3M, driven by higher demand, helping gross margin improve to 91.6%. While net income remained negative at -$68.9M in FY2025, performance improved from a net loss of -$130.4M in FY2024. Over the trailing twelve months ended June 30, 2026, revenue totaled $450.9M with an operating margin of 49.8% and a net profit margin of 30.7%. In the quarter ended June 30, 2026, quarterly revenue grew 1842.7% year-over-year, delivering trailing twelve-month EPS of $1.39.

As of June 30, 2026, Liquidia held $284.2M in cash and short-term investments against total debt of $128.9M, resulting in a net cash position of $155.2M. Total assets stood at $521.9M alongside shareholders' equity of $195.1M. Liquidity is supported by a current ratio of 2.31 and a debt-to-equity ratio of 0.66. Capital expenditures in FY2025 were $4.3M, and free cash flow was -$40.0M. The company does not conduct share repurchases, and its share count grew 98.5% over the past 5 years.

At a last close of $34.35, Liquidia carries a market capitalization of $3.07B and an enterprise value of $5.94B. The stock trades at a trailing price-to-earnings multiple of 24.7x, comparable to the 24.6x median of its US-listed Healthcare peers, while its forward price-to-earnings ratio of 10.5x sits below the peer median of 17.3x. Its price-to-sales ratio is 6.8x compared to the peer median of 4.1x, and EV/EBITDA is 33.4x against the peer median of 12.0x. Over the past year, Liquidia returned 48.2% versus 16.8% for the S&P 500, and its 5-year return reached 973.4% against 83.0% for the index.

Wall Street coverage on Liquidia includes 4 Strong Buy, 2 Buy, and 2 Hold ratings, with no Sell or Strong Sell ratings. The consensus mean price target is $54.38, representing 58.3% upside above the last close of $34.35. For the fiscal year ending December 31, 2026, consensus estimates project EPS of $2.03 on revenue of $717.0M. For FY2027, 7 analysts project EPS of $2.19 on revenue of $762.1M. Liquidia beat EPS estimates in 2 of the past 4 quarters, and its next earnings date is November 2, 2026.

This page is an AI-written research summary of Liquidia Corporation (LQDA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: LQDA income statement, LQDA balance sheet, LQDA key metrics, LQDA analyst forecast, LQDA chart. See the LQDA stock overview for the latest quote and news.